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Alltrans-retinoic acid metabolites significantly inhibit
the proliferation of MCF-7 human breast cancer cells in
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Summary All-trans-retinoic acid (ATRA) is well known to inhibit the proliferation of human breast cancer cells. Much less is known about the
antiproliferative activity of the naturally occurring metabolites and isomers of ATRA. In the present study, we investigated the antiproliferative
activity of ATRA, its physiological catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA and isomers 9-cis-RA and 13-cis-RA in MCF-7 human breast
cancer cells by bromodeoxyuridine incorporation. MCF-7 cells were grown in steroid- and retinoid-free medium supplemented with growth
factors. Under these culture conditions, ATRA and its naturally occurring catabolites and isomers showed significant antiproliferative activity
in MCF-7 cells in a concentration-dependent manner (10-11 M to 10- M). The antiproliferative activity of ATRA catabolites and isomers was
equal to that of the parent compound ATRA at concentrations of 10- M and 107 M. Only at 10-6 M were the catabolites and the stereoisomer
13-cis-RA less potent. The stereoisomer 9-cis-RA was as potent as ATRA at all concentrations tested (10-11 M to 10- M). In addition, we show
that the catabolites and isomers were formed from ATRA to only a limited extent. Together, our findings suggest that in spite of their high
antiproliferative activity the catabolites and isomers of ATRA cannot be responsible for the observed growth inhibition induced by ATRA.
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Retinoic acid (RA) has been shown to exert antiproliferative and
differentiation-inducing effects on cancer cells both in vitro and in
vivo (Gudas etal, 1994; Moon etal, 1994). These effects are medi-
ated through binding to nuclear retinoid receptors, namely the
RA receptors (RARs) and the retinoid X receptors (RXRs). Both
receptors are members of the nuclear hormone receptor super-
family and function as ligand-dependent transcription factors
(Chambon, 1996). The RAR family is activated both by ATRA
andby 9-cis-RA, whereas the RXR family is activated exclusively
by 9-cis-RA (Chambon, 1996). The ability of the natural
stereoisomer 13-cis-RA to bind to RARs is controversial.
Diversity in the control of gene expression by RA exists
because of the complexity at different levels of the signalling
pathway. An important level in this complex retinoid signalling
pathway is represented by the existence of natural metabolites of
all-trans-RA (ATRA), whose synthesis may be modulated cell
specifically (Napoli, 1996). ATRA metabolism has been studied in
a variety oftissues and a number ofmetabolites have been identi-
fied (Figure 1). One important catabolic pathway for ATRA is
initiated by hydroxylation at the four position oftheP-ionone ring
ofATRA to yield 4-hydroxy-ATRA (Frolik et al, 1979; Roberts et
al, 1980). This step is catalysed by a cytochrome P450-dependent
ATRA 4-hydroxylase (Roberts et al, 1980; White et al, 1996).
4-Hydroxy-ATRA is further oxidized via 4-oxo-ATRA to more
polar metabolites (Roberts et al, 1980). This latter step involves at
least one other, presently unknown, cytochrome P450-dependent
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enzyme (Roberts et al, 1980; Van Wauwe et al, 1994). Epoxidation
of ATRA yields 5,6-epoxy-ATRA (McCormick et al, 1978).
ATRA can also isomerize to 9-cis-RA and 13-cis-RA, an obvi-
ously non-enzymatic process (Urbach and Rando, 1994).
Cancer cells have been shown to possess RA catabolic activity.
Oxidative catabolism ofRA to morepolarmetabolites was observed
in N-methyl-N-nitrosourea-induced mammary tumours in the rat
(Bhat and Lacroix, 1989), in rat Dunning R3327G prostate tumours
(Krekels et al, 1996), F9 mouse teratocarcinomacells (Williams and
Napoli, 1985), LLC-PK1 pig kidney cancer cells (Napoli, 1986),
BA-HAN-IC ratrhabdomyosarcoma cells (Biesalski et al, 1990), as
well as in the human breast cancer cells MCF-7 (Wouters et al,
1992; Krekels et al, 1997) and T47D (Han and Choi, 1996).
Recently, Takatsuka et al (1996) showed a positive relationship
between metabolism of ATRA in human breast cancer cells and
the antiproliferative activity of ATRA, suggesting that an unde-
fined metabolite ofATRA, rather than the parent compound itself,
could be responsible for the observed growth inhibition induced
by ATRA. To date, only limited and conflicting results have been
published concerning the activity ofthe naturally occurring ATRA
metabolites in tumours. To clarify these points, we studied the
antiproliferative activity of ATRA, its physiological catabolites
4-oxo-ATRA and 5,6-epoxy-ATRA and isomers 9-cis-RA and 13-
cis-RA in MCF-7 cells using a bromodeoxyuridine incorporation
assay. Bromodeoxyuridine labelling is considered an accurate
method to measure cell proliferation because it is a direct assay of
DNA synthesis (Dolbeare, 1995). Furthermore, the antiprolifera-
tive activities could only be properly studied in a steroid- and
retinoid-free medium, because of the presence of endogenous
retinoids in serum. Therefore, MCF-7 cells were grown in a
phenol red-free medium supplemented with charcoal-treated fetal
bovine serum and growth factors.
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Figure 1 Chemical structures of ATRA, its naturally occurring isomers and catabolites arising from two different catabolic pathways
MATERIALS AND METHODS
Drugs and chemicals
ATRA was obtained from Serva (Heidelberg, Germany) and 13-
cis-RA was purchased from Eastman Kodak (Rochester, NY,
USA). 9-cis-RA, 4-oxo-ATRA and 5,6-epoxy-ATRA were a
generous gift from Dr M Klaus (Hoffmann La Roche, Basle,
Switzerland). All retinoids were dissolved in ethanol to an initial
concentration of4 mm and appropriately diluted in culture medium.
The final solvent concentration during the proliferation studies was
always < 0.5% (v/v). The retinoid stock solutions were checked for
purity using HPLC analysis. Experiments with retinoids were
always performed in a dark room with yellow illumination.
Preparation of dextran-coated charcoal (DCC)-treated
fetal bovine serum (FBS)
DCC-treated FBS was prepared as described by Horwitz and
McGuire (1978). Briefly, FBS (Life Technologies, Paisley, UK)
was heat inactivated by a 30-min incubation at 56°C. Activated
charcoal [0.25% (w/v); Sigma, St Louis, USA) was coated
overnight at 4°C with dextran (0.025% (w/v); Pharmacia, Uppsala,
Sweden) in 0.01 M Tris-HCl (pH 8.0). Then, 100 ml of this
suspension was pelleted by centrifugation and 50 ml ofheat-inacti-
vated FBS was incubated with the resulting DCC pellet for 45 min
at 45°C. This procedure was repeated, and finally the activated
charcoal was removed from the FBS by centrifugation. DCC-
treated FBS was sterilized by passage through a 0.22 gm Millipore
filter (low protein binding) and stored at -20°C until use. The effi-
ciency of this procedure was assessed by the addition of a trace
Table 1 Efficiency of oestrogen and retinoid extraction from fetal bovine
serum by dextran-coated charcoal treatment
Amount of tritiated label after
DCC treatment (%)
17,B-Oestradiol 0.64 ± 0.17
ATRA 6.43 ± 0.52
Retinol 35.78 ± 6.78
Mean ± s.d. (n = 3).
amount of [6,7-3H(N)]oestradiol (Dupont NEN, Boston, MA,
USA), [1l,12-3H(N)]retinol (Dupont NEN, Boston, MA, USA)
and [11,12-3H(N)]ATRA (Dupont NEN, Boston, MA, USA).
Cell culture
Stockcultures ofMCF-7 human breast cancercells, purchased from
the American Type Culture Collection (Rockville, MD, USA), were
cultured in Dulbecco's modified Eagle medium (DMEM) with
4.5 g 1-l of glucose supplemented with 10% (v/v) FBS, 2 mM L-
glutamine, 1 mm sodium pyruvate and 50,g ml-' gentamicin (all
reagents from Life Technologies). The MCF-7 subclone used in this
study has been characterized previously (Van heusden et al, 1996).
Cells were grown in a humidified incubator (5% carbon dioxide,
95% air) at 37°C and were Mycoplasma-free as tested by the
Mycoplasma TC kit (Gen-Probe Incorporated, CA, USA).
For the proliferation studies, the MCF-7 cells were cultured
for 6 days in phenol red-free DMEM containing 5% (v/v) DCC-
treated FBS, 4.5 g -1 ofglucose, 2 mM L-glutamine, 1 mM sodium
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Figure 2 Concentration-response curves showing the antiproliferative
effects of ATRA (A), its catabolites 4-oxo-ATRA (B) and 5,6-epoxy-ATRA (C)
and its isomers 9-cis-RA (D) and 13-cis-RA (E) in MCF-7 cells. Cells were
cultured for 7 days in the presence of test compounds. Cell proliferation was
measured by BrdU incorporation, as described in Materials and methods.
Results are presented as means ± s.d. of three (A, D, E) orfive (B, C)
experiments. *P< 0.01 and **P< 0.001 vs control cells (Mann-Whitney
U-test). #P < 0.01 vs ATRA-treated cells (Mann-Whitney U-test)
pyruvate, 50 jig ml-' ofgentamicin, 30 nM sodium selenite and 10
jg ml-' oftransferrin (all reagents from Life Technologies). Then,
cells were seeded onto Chamber Slides (Nunc, Naperville, IL,
USA) at a concentration of 15 000 cells per chamber. Chamber
Slides has been coated with 50 jg ml-' of poly-L-lysine one day
before use. Cells were allowed to attach for 24 h and thereafter the
medium was supplemented with growth factors (10 jig ml' offinal
concentration insulin (Life Technologies) and 5 ng ml' of final
concentration basic fibroblast growth factor (Life Technologies))
and retinoids (concentration ranging from 10-" M to 10 6 M). Cells
were grown underthese conditions for7 days with medium changes
3 and 6 days after seeding.
Bromodeoxyuridine (BrdU) detection
After 7 days of culture with retinoids as described above, MCF-7
cells were labelled with 100 gM BrdU for 2.5 h and fixed.
Incorporated BrdU was visualized by immunofluorescence
staining using the Tyramide Signal Amplification (TSA)-Direct kit
(Green) (DuPont NEN Life Science Products, Boston, MA, USA)
as described in detail previously (Van heusden et al, 1997).
The BrdU-labelling index was defined as the proportion of
BrdU-positive cells, representing cells in S-phase and was calcu-
lated by counting cells under a fluorescence microscope
(Axiophot, Zeiss, Germany) with a dual filter set for simultaneous
visualization of fluorescein and propidium iodide signals.
Approximately 800 cells were counted twice for each test
compound per experiment. The average results are presented as
means ± s.d. ofthree or five experiments.
HPLC analysis
Confluent MCF-7 cells, cultured in medium containing 5% DCC-
treated FBS, were treated for 24 h with 106 M ATRA to induce
ATRA catabolism (Wouters et al, 1992; Krekels et al, 1997). Cells
were then washed twice with 25 ml ofculture medium, trypsinized
and harvested. Cells were resuspended at a concentration of
4 x 106cells ml-'. This cell suspension (450 jl) was incubated with
10-7M [11,12 -3H(N)]ATRA for various times. Aftercentrifugation
for 10 min at 780g, the supernatant was analysed for the presence
ofATRA metabolites and isomers.
Analysis ofATRA metabolites
Reverse-phase HPLC analysis was carried out on a Varian HPLC
system consisting of a HPLC pump 9010, an autosampler 9095
and a diode array detector (Polyview, 9065). The STAR 4.0 data
software (Varian, Harbor City, CA, USA) was used to analyse the
chromatograms. Radioactivity in the eluate was monitored on-line
by ,3-counting (Packard Radiomatic radioactivity monitor) using
Ultima-flo M (Packard, Meriden, CT, USA) as the scintillation
solvent. The samples (150 jil) were analysed on a Zorbax 5C8
column (4.6 mm i.d. x 250 mm, 5 jum; Chrompack). The mobile
phase was methanol/2% acetic acid/acetonitrile (1.5:93:5.5)
containing 40 mM ammonium acetate (solvent A). Solvent B
consisted of methanol/2% acetic acid/acetonitrile (15:30:55)
containing 40 mm ammonium acetate and solvent C was 100%
methanol. A linear gradient at a flow rate of 1 ml min-' was
performed for 25 min from 24% A-76% B to 15% A-85% B.
The solvent was then changed to 50% B-50% C in 15 min. To
elute unchanged ATRA the solvent was changed to 100% C
after 40 min.
Analysis ofATRA isomers
For the separation ofthe isomers ofATRA the same HPLC equip-
ment was used. Samples (150 jl) were analysed on a Novapak
column (3.9 mm i.d. x 300 mm). Solvent D was methanol/2%
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Figure 3 Chromatograms illustrating the metabolism and isomerization of ATRA in MCF-7 cells grown in medium containing 5% DCC-treated FBS. Cells were
incubated for 24 h with 10-6 M ATRA to induce ATRA catabolism, washed twice and collected. Cells were then incubated for 4 h with 10-7 M [3H]ATRA and the
supernatant was analysed by reverse-phase HPLC for the presence of metabolites (A) and isomers (B). I, very polar metabolites; II, intermediate polar
metabolites; III, unchanged RA; IV, apolar peak
acetic acid/acetonitrile (15:30:55) containing 40 mM ammonium
acetate. Solvent E consisted of methanol/2% acetic acid/acetoni-
trile (20:20:60) containing 40 mM ammonium acetate and solvent
F was 100% methanol. The mobile phase was 50% D-50% E for
30 min at a flow rate of 1 ml min-'. Then a linear gradient was
performed to 100% F.
Statistical analysis
Data were analysedusing the two-tailed Mann-Whitney U-test using
the Stat View II software (Abacus Concepts, Berkeley, CA, USA).
Significance was defined at the level of *P < 0.01 and **P < 0.001.
RESULTS
Dextran-coated charcoal treatment of FBS efficiently
removed oestrogens and retinoids
The efficiency ofheat inactivation and subsequent DCC treatment
to remove steroids and retinoids from FBS was assessed by the
addition of trace amounts of tritiated 17p-oestradiol, ATRA and
retinol. As shown in Table 1, this procedure efficiently removed
17p-oestradiol and ATRA, and retinol to a lesser extent. 17p-
Oestradiol was removed for more than 99%, ATRA for more than
93%, and retinol for 64%. When the tritiated compounds were
preincubated with FBS for 24 h before DCC-treatment, similar
results were obtained (data not shown).
ATRA and its naturally occurring catabolites and
isomers significantly inhibit MCF-7 cell proliferation
MCF-7 cells, grown in medium containing 5% DCC-treated FBS,
showed a BrdU labelling index of 8.0 ± 1.0% (n = 3). Cells were
stimulated to proliferate by the addition of 10 ,ug ml-' insulin and
5 ng ml- basic fibroblast growth factor, resulting in a BrdU-
labelling index of 25.2 ± 1.4% (n = 5).
Under these culture conditions, ATRA inhibited the prolifera-
tion of MCF-7 cells in a concentration-dependent manner, at
concentrations from 10-8 M to 10"M (Figure 2A), which was
reflected by a decrease in the BrdU-labelling index. At a concen-
tration of 10 M, ATRA inhibited MCF-7 cell proliferation by
61 ±4% (n=3).
Figure 2B shows that the ATRA catabolite 4-oxo-ATRA
decreased the labelling index at concentrations ranging from
10-8 M to 10 M. At a concentration of 10- M, cell proliferation
was inhibited by 37 ± 11% (n = 5).
5,6-epoxy-ATRA, another catabolite of ATRA, decreased the
BrdU labelling index at 10-8 M to 106 M the same extent as 4-oxo-
ATRA (Figure 2C).
The stereoisomer 9-cis-RA (Figure 2D) also inhibited MCF-7
cell proliferation in a concentration-dependent manner (10-8 M to
10" M). Note that 9-cis-RA was equipotent compared with ATRA
at all concentrations tested.
Figure 2E shows the antiproliferative activity of the stereo-
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Figure 4 Metabolism and isomerization of ATRA in MCF-7 cells grown in
medium containing 5% DCC-treated FBS. Cells were incubated for 24 h with
10-6 M ATRA to induce ATRA catabolism, washed twice and collected. Cells
were then incubated for various times with 107 M [3H]ATRA and the
supernatant was analysed by reverse-phase HPLC for the presence of
metabolites and isomers *, ATRA; A, very polar metabolites; V 9-cis-RA;
*, 13-cis-RA; *, intermediate polar metabolites
isomer 13-cis-RA. At concentrations ranging from 10-8 M to 10- M,
13-cis-RA decreased the BrdU labelling index to the same extent as
the ATRA catabolites 4-oxo-ATRA and 5,6-epoxy-ATRA.
In vitro metabolism and isomerization of ATRA in
MCF-7 cells
MCF-7 cells, grown in medium containing 5% DCC-treated FBS,
were pretreated for 24 h with 10 M ATRA to induce ATRA catab-
olism. Cells were then incubated with 10-7 M [3H]ATRA for 4 h
and the supematant was analysed for the presence of labelled
ATRA catabolites and isomers by HPLC analysis. As shown in
Figure 3A, MCF-7 cells converted ATRA into very polar metabo-
lites (retention time 2-11 min) and several metabolites of inter-
mediate polarity (retention time 16-25 min). In the absence of
cells no polar metabolites could be detected (data not shown).
Combined, the intermediate and very polar metabolites accounted
for about 60% oftotal recoveredradioactivity. Peaks were detected
(Figure 3A) co-eluting with authentic 4-hydroxy-ATRA (retention
time 19 min) and4-oxo-ATRA (retentiontime, 20.3 min). Figure4
shows that the intermediate polar metabolites were formed only to
a limited extent (less than 10%) and their amount did not increase
as a function oftime. Increasing amounts ofvery polar metabolites
were formed from ATRA as a function oftime (Figure 4). No peak
co-eluting with authentic 5,6-epoxy-ATRA (retention time,
37 min) could be detected in the culture medium ofcells that were
pretreated to induce ATRA catabolism (Figure 3A). In the culture
medium of cells that were not pretreated with ATRA or in the
absence of cells, 5,6-epoxy-ATRA could not be detected at time
points ranging from 30 min to 24 h (data not shown). Other polar
metabolites were present in the cell culture medium (Figure 3A)
but their nature remains to be identified. MCF-7 cells also
converted ATRA into an apolar metabolite, that was not detected
in the absence ofcells.
Figure 3B shows the isomers of ATRA that were formed when
MCF-7 cells, pretreated for 24 h with 106 M ATRA, were incu-
bated with 10-7 M [3H]ATRA. After 4 h, only about 30% of total
radioactivity was recovered in the RA peak, i.e. ATRA and its
stereoisomers 9-cis-RA and 13-cis-RA. This RA peak consisted of
about 83% of ATRA, 8% of 13-cis-RA and 7% of 9-cis-RA.
Similar isomer composition of the RA peak was obtained with
cells that were not pretreated with ATRA and in the absence of
cells (data not shown). After 24 h, only about 11% of total radio-
activity was recovered in the RA peak of MCF-7 cells that were
pretreated with ATRA (Figure 4). In the absence of cells about
80% of total radioactivity was recovered in the RA peak (data not
shown). Under both culture conditions, the relative isomer compo-
sition was about 71% ATRA, 12% 13-cis-RA and 8% 9-cis-RA.
An additional peak (peak i, Figure 3B) could be detected but its
nature remains unknown.
DISCUSSION
The present study demonstrates that not only ATRA itself, but also
its naturally occurring catabolites 4-oxo-ATRA and 5,6-epoxy-
ATRA as well as its isomers 9-cis-RA and 13-cis-RA possess
significant antiproliferative activity in MCF-7 human breast cancer
cells, grown in a steroid- and retinoid-free medium. A significant
antiproliferative activity equal to that ofATRA, was observed with
these metabolites at concentrations of 10-8 M and 10-7 M. At a
concentration of 10 6M, the ATRA catabolites and the stereoisomer
13-cis-RA were less potent than ATRA. The stereoisomer 9-cis-
RA was as potent as ATRA at all concentrations tested (10-11 M to
106 M). As these catabolites and isomers were formed to only a
limited extent, our findings suggest that they cannot be responsible
for the observed growth inhibition induced by ATRA.
The antiproliferative activity of ATRA and its naturally occur-
ring catabolites and isomers could only be properly studied in a
steroid- and retinoid-free culture medium. Forthis purpose, phenol
red-free medium (Berthois et al, 1986) was used supplemented
with DCC-treated FBS (Horwitz and McGuire, 1978). DCC-treat-
ment ofFBS is well known to remove endogenous steroids present
in the serum (Horwitz and McGuire, 1978). In this study, we
showed that also ATRA was efficiently removed by DCC-treat-
ment. This would result in a final concentration of 1.3 x 10-"' M to
4.5 x 10-"1 M ATRA in the culture medium, calculated from ATRA
levels present in human plasma, i.e. 4-14 nM. To date, only indi-
rect evidence suggested that retinoids could be removed from the
serum by DCC treatment (Mummery et al, 1991). Retinol, a
possible source ofRA, was harder to extract and about 40% could
not be removed. We assumed that the remaining amount ofretinol
did not interfere with our results as MCF-7 cells are unable to
convert retinol into ATRA (Krekels et al, 1997).
The antineoplastic activity of synthetic retinoids, such as
for example N-(4-hydroxyphenyl)retinamide, has been amply
described. In contrast, limited and conflicting results have been
reported about the activity of naturally occurring ATRA metabo-
lites in tumour cells. The catabolite 4-oxo-ATRA has been shown
to bind to RARs (Pijnappel et al, 1993). Furthermore, both 4-oxo-
ATRA and 5,6-epoxy-ATRA can activate RAR-dependent gene
transcription in co-transfected CV-1 cells (Duell et al, 1992).
However, their activity in our study was higher than would have
been expected from previous reports where these catabolites were
found to be less potent than ATRA in (a) the inhibition of growth
and the inhibition of hormone isobutylmethylxanthine-inducible
tyrosinase activity of Cloudman S-91 mouse melanoma cells
(Lotan et al, 1980; Reynolds et al, 1993); (b) the induction of
differentiation of F9 mouse teratocarcinoma cells as measured by
ELISA for laminin (Williams et al, 1987); and (c) the induction of
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differentiation and inhibition of proliferation of BA-HAN-IC rat
rhabdomyosarcoma cells (Ramp et al, 1994). In contrast, both
catabolites have been reported to be virtually inactive (Frolik et al,
1979; Silva et al, 1987). In our MCF-7 model system, the catabo-
lites 4-oxo-ATRA and 5,6-epoxy-ATRA were as potent as ATRA
at concentrations of 10-8 M and 10-7 M, but were twofold less
potent at 10-6 M. It is clear that a complex phenomenon is occur-
ring for which there is no obvious explanation. It is very unlikely
that the observed antiproliferative activity of 4-oxo-ATRA and
5,6-epoxy-ATRA was due to conversion back to ATRA as the
reactions involved in their formation are irreversible (Roberts et al,
1980; Napoli et al, 1982). Although conversion to other active
retinoids is conceivable, such compounds have yet to be identified
(Reynolds et al, 1993). To date, only in non-tumour models,
namely in a model of positional specification (Pijnappel et al,
1993) and in spermatogonia (Gaemers et al, 1996), has 4-oxo-
ATRA been shown to be as potent as ATRA.
ATRA catabolism, under the present culture conditions, was
induced to the same extent, as described previously (Wouters et al,
1992; Krekels et al, 1997). Only the supematant was analysed for
the presence of ATRA metabolites. We have previously shown that
in the cell extract the same overall metabolite profile can be found
(Wouters et al, 1992). Using HPLC analysis peaks were identified
that co-eluted with authentic 4-hydroxy-ATRA and 4-oxo ATRA.
No 5,6-epoxy-ATRA could be detected under basal culture condi-
tions nor after the induction of ATRA catabolism, indicating that
5,6-epoxy-ATRA was either not formed in vitro or formed in quan-
tities below the detection limit. Therefore, it is unlikely that 5,6-
epoxidation is a major catabolic pathway of ATRA in MCF-7 cells.
In addition, other polar metabolites could be detected but their
nature remains to be elucidated. We cannot exclude the possibility
that these metabolites possess antiproliferative activity. In this
context it is interesting to remark, however, that we have shown
previously that the antiproliferative activity of ATRA can be
enhanced by the addition of an inhibitor of ATRA catabolism
(Wouters et al, 1992; Van heusden et al, 1996), suggesting that
catabolism ofATRA is not necessary to inhibit MCF-7 cell prolifer-
ation. The exact nature ofthe apolar peak, which has been described
previously (Wouters et al, 1992), also remains to be determined.
Recently, Takatsuka et al (1996) showed a positive relationship
between ATRA-induced growth inhibition ofhuman breast cancer
cells and intracellular ATRA metabolism, suggesting that a
metabolite ofATRA, rather than the parent compound itself, could
be responsible for the observed growth inhibition. It is important
to note, however, that these experiments were conducted under
serum-free conditions, resulting in an altered bioavailability of
ATRA to cells (Hodam and Creek, 1996). Our data showed that 4-
oxo-ATRA and 5,6-epoxy-ATRA are strong inhibitors of MCF-7
cell proliferation. However, as 5,6-epoxy-ATRA could not be
identified in our cell culture system and 4-oxo-ATRA was formed
to only a limited extent, our results do not favour the hypothesis
that these catabolites are responsible for the observed growth inhi-
bition when given ATRA.
The ability of ATRA to isomerize in cell culture (Urbach and
Rando, 1994) further complicates the interpretation of its antipro-
liferative activity. In the present study, isomerization of ATRA to
9-cis-RA and 13-cis-RA was also observed, but only to a limited
extent. This process was not enzymatic as it also occurred in the
absence of cells, in agreement with previous results (Urbach and
Rando, 1994). The major isomer detected was the all-trans form of
RA. The naturally occurring stereoisomer 9-cis-RA acts as a pan
agonist that can bind and activate both RARs and RXRs
(Chambon, 1996). 9-cis-RA was equipotent to ATRA in inhibiting
MCF-7 cell proliferation at all concentrations tested, in agreement
with previous reports (Rubin et al, 1994). The ability of the natu-
rally occurring stereoisomer 13-cis-RA to bind and transactivate
RARs is controversial. The antiproliferative activity of 13-cis-RA
has been described to be less (Redfern et al, 1990) or equal (Frey
et al, 1991) to that of ATRA. In our experiments, 13-cis-RA, at
concentrations of 10-8 M and 107 M, was equipotent to ATRA in
inhibiting the growth of MCF-7 cells, in agreement with previous
reports (Frey et al, 1991) and with its therapeutic effect in some
forms ofcancer.
In conclusion, we can state that the naturally occurring catabo-
lites and isomers of ATRA show significant antiproliferative
activity in MCF-7 human breast cancer cells. However, as these
catabolites and isomers were formed from ATRA to only a limited
extent, our findings suggest that they cannot be responsible for the
observed growth inhibition induced by ATRA.
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